Goodwin advised SpringWorks Therapeutics, Inc. on the offering. American precision medicine company SpringWorks Therapeutics (Nasdaq: SWTX) has closed a public offering of 10,905,171 shares of its common...
You must be a Standard 1 Year member to access this content.
Goodwin advised Scholar Rock Holding Corporation on the offering. Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Entrada Therapeutics, Inc. on the deal. Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its global collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to focus...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised SpringWorks Therapeutics on the deal. SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced its private placement transaction with a select group of institutional investors to issue...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz and Maples and Calder represented Social Capital Suvretta Holdings Corp. I in the transaction. Goodwin Procter advised Akili, while Skadden, Arps,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Rubius Therapeutics on the deal. Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
